Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director, Western U.S. The appointment reflects the company's focus on expanding its presence in a key strategic region and supporting the continued adoption of Nociscan.
Dan Keefe will lead commercial efforts across the Western region, building on Aclarion's existing footprint. The company has established a growing presence across the Western U.S., with engagement spanning both academic institutions and high-volume private practice spine centers, supported by strong volume growth. The expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies. His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan," said Brent Ness, Chief Executive Officer of Aclarion.
Keefe joins Aclarion with more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across the Northern California region. Throughout his career, Keefe has demonstrated success in building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments.
"I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community. The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice," said Daniel Keefe.
An estimated 266 million people worldwide live with chronic low back pain, making it one of the most pervasive health challenges. Aclarion's Nociscan solution is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
For more information on Nociscan, visit www.aclarion.com or view the site map here.
